Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $301

Benzinga Newsdesk www.benzinga.com Positive 62.9%

Neg 0% Neu 0% Pos 62.9%

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $232 to $301.